Renaissance Capital logo

BBRX News

Experiencing withdrawals: Braeburn Pharmaceuticals officially withdraws $150 million IPO

Braeburn Pharmaceuticals logo

Braeburn Pharmaceuticals, which is commercializing a long-acting implant for treatment of opioid addiction, withdrew its plans for an initial public offering on Wednesday, citing terms available from the market. It had filed to raise $150 million by offering...read more

Bad apple: Opioid addiction biotech Braeburn Pharmaceuticals postpones $150 million IPO

Braeburn Pharmaceuticals logo

Braeburn Pharmaceuticals, which is commercializing a long-acting implant for treatment of opioid addiction, postponed its IPO on Thursday. It had filed to raise $150 million by offering 7.7 million shares at a price range of $18 to $21. The Princeton,...read more

US IPO Week Ahead: 7-IPO week led by mega REIT and world's largest for-profit school

LAUR

The 2017 IPO market continues its torrid pace with seven deals on the IPO calendar. Blackstone's home-rental REIT, Invitation Homes, aims to raise $1.5 billion in the largest US IPO since October 2015. The week's other two big deals, LBO Laureate Education ...read more

US IPO Weekly Recap: AppDynamics taken out, 6 IPOs price

APPD

The star was taken, but the show must go on. Six companies went public this week, but AppDynamics (APPD) was notably missing as Cisco (Nasdaq: CSCO) acquired it for $3.7 billion the night before its scheduled pricing. Cisco paid a 68% premium to the high...read more